

**EXPRES** 

DOCKET .: 176/60792 (6-11415-868) AIL NO.: **EL542863765US** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

## UTILITY PATENT APPLICATION TRANSMITTAL FORM (only for new nonprovisional applications under 37 CFR 1.53(b)

ASSISTANT COMMISSIONER FOR PATENTS Washington, D.C. 20231

**BOX: PATENT APPLICATION** 

SIR:

Transmitted herewith for filing is the patent application (including Specification, Claims, and Abstract, 106 pages) of:

\*\*If a CONTINUING APPLICATION, please mark where appropriate and supply the requisite

Inventor : Mahin D. Maines

For : BILIVERDIN REDUCTASE FRAGMENTS AND VARIANTS, AND METHODS

OF USING BILIVERDIN REDUCTASE AND SUCH FRAGMENTS AND

**VARIANTS** 

infor	mation below and in a preliminary amendment:	
	continuation [ ] divisional [ ] Continuation-In-Part (CIP) prior application Serial No	
Pri	or application information: Examiner : Art Unit :	
Encl	osed are:	
[ <b>X</b> ]	23 sheets of informal drawings.	
[]	Signed Combined Declaration and Power of Attorney ( pages).	
[.]	<b>Copy</b> of <b>signed</b> Combined Declaration and Power of Attorney ( pages) from a prior application (1.63(d) (for continuation/divisional).	
[]	<b>Signed</b> statement deleting inventor(s) named in prior application ( pages) (1.63(d)(2) and 1.33(b)).	
[]	<b>Incorporation By Reference</b> : The entire disclosure of the prior application, from which a <b>copy</b> of the oath or declaration is supplied herewith, is considered as being part of the disclosure of the enclosed application and is hereby incorporated by reference therein.	
[]	Assignment ( pages) of the invention to	
[]	Assignment Transmittal Letter.	
[]	Certified copy of a foreign priority document.	
[]	Associate power of attorney.	

ت

]	Verified statement to establish small entity status ( pages) (newly signed or copy filed in prior application).
]	Preliminary Amendment ( pages).
]	Information Disclosure Statement, form PTO-1449 ( pages) and references.
X]	<u>UNSIGNED</u> Combined Declaration and Power of Attorney (2 pages).
X]	Statement in Accordance with 37 CFR § 1.821(f) and computer readable 3.5" Diskette.
X]	Sequence Listing (21 pages).
X]	A self-addressed, prepaid postcard acknowledging receipt.

The Filing fee has been calculated as shown below:

	(Col. 1)	(Col. 2)		
FOR:	NO. FILED	NO. EXTRA		
BASIC FEE	xxxxxxx	xxxxxxx		
TOTAL CLAIMS	67 - 20 =	47		
INDEP CLAIMS	5 - 3 =	2		
[ ] MULTIPLE DEPENDENT CLAIM PRESENTED				

\*If the Total Claims are less than 20 and Indep. Claims are less than 3, enter "0" in Col. 2

**SMALL ENTITY** 

**RATE FEE** XXXX \$345 x 9 =\$423 x 39 =\$78 x130 =\$846 **TOTAL** 

LARGE ENTITY

<u>OR</u>

<u>OR</u>

<u>OR</u>

<u>OR</u>

OR

<u>OR</u>

RATE	FEE
XXXX	\$690
x 18 =	\$
X78 =	\$
x260 =	\$
TOTAL	\$

- Please charge my Deposit Account No.\_\_\_\_\_ in the amount of \$ A duplicate copy of this sheet is enclosed.
- [X] A check in the amount of \$846.00 to cover the filing fee is enclosed.
- [X] Address all future communications to:

Michael L. Goldman NIXON PEABODY LLP Clinton Square, P.O. Box 31051 Rochester, New York 14603

Date: June 28, 2000

Edwin V. Merkel Registration No. 40,087

NIXON PEABODY LLP Clinton Square, P.O. Box 31051 Rochester, New York 14603

Telephone: (716) 263-1128 Facsimile: (716) 263-1600

R411187.1

TITLE:

Biliverdin Reductase Fragments and Variants, and Methods Of Using Biliverdin Reductase and Such Fragments and Variants

**INVENTOR:** 

Mahin D. Maines

DOCKET NO.:

176/60792 (6-11415-868)